Management Consulting Pharma SRL
Management Consulting Pharma reported total assets of 155,710 € at the end of the 2025 financial year (annual accounts filed with the NBB on 04 Dec 2025).
The score of Management Consulting Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Management Consulting Pharma's annual accounts
| 2025 | |
|---|---|
| Net result | 101,238 € |
| Equity | 105,238 € |
| Cash | 84,308 € |
| EBITDA | 130,455 € |
| Total assets | 155,710 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 04 Dec 2025
Management Consulting Pharma's financial analysis
- Solvency67.6%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Management Consulting Pharma
Management Consulting Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1010.773.751
- VAT number
- BE1010773751
- Peppol
- Registered · 0208:1010773751 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Jun 2024
- Registered office
- 1360 Perwez
- Latest accounts
- 2025 · filed on 04 Dec 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Management Consulting Pharma (SRL) has been based in Perwez since 2024, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 101,238 € and equity of 105,238 €; its revenue is not published. Its solvency stands at 67.6%, above the median of its sector (41.5%).
Companies similar to Management Consulting Pharma
Companies in the same business, of comparable size and area, outside its group.
- BERA Business and other management consultancy activities Antwerp · balance sheet 140,519 €
- CosProf Studio Business and other management consultancy activities Niel · balance sheet 120,568 €
- Novafontis Business and other management consultancy activities Liège · balance sheet 131,719 €
- Swilem Pharmaceuticals Business and other management consultancy activities Evere · balance sheet 292,979 €
- Galeni K. Business and other management consultancy activities Zutendaal · balance sheet 67,285 €
- Lintström Business and other management consultancy activities Schilde · balance sheet 64,321 €
- Berghman Business and other management consultancy activities Wervik · balance sheet 426,772 €
- ENNC Retail sale of pharmaceutical products Oud-Heverlee · balance sheet 149,458 €
Frequently asked questions about Management Consulting Pharma
What is the revenue of Management Consulting Pharma?
Management Consulting Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Management Consulting Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE1010773751 for Management Consulting Pharma, if the company is VAT-registered. Its company number (CBE) is 1010.773.751.
Where is the registered office of Management Consulting Pharma?
According to the CBE register, the registered office of Management Consulting Pharma is in 1360 Perwez.
What is the equity of Management Consulting Pharma?
At the close of the 2025 financial year, the equity of Management Consulting Pharma amounts to 105,238 €, a solvency of 67.6% of total assets.
Who manages Management Consulting Pharma?
The register lists 1 active mandates at Management Consulting Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Management Consulting Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →